BIOMAT Database Logo BIOMAT Database Logo

Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. 2001

M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Department of Virology, Pitié-Salpêtrière Hospital, Paris, France.

OBJECTIVE Mutations usually associated with zidovudine exposure have been observed in zidovudine-naive patients treated by stavudine in combination. These mutations were named thymidine analogue mutations (TAMs). This fact, combined with phenotypical and biochemical findings provided additional evidence for cross-resistance between zidovudine and stavudine. A recent genotypic study in naive patients receiving stavudine/didanosine combination showed emergence of TAMs and a multidrug-resistance mutation (MDR), Q151M, in 36 and 10% of cases, respectively. Stavudine plus lamivudine is one of the most used binucleoside associations in the antiretroviral combinations. The objective of this study was to assess the genotypic changes in the HIV-1 reverse transcriptase (RT) gene in antiretroviral-naive patients treated by stavudine plus lamivudine. METHODS We analysed the RT gene of 44 HIV-1 patients, naive of antiretroviral therapy, who were treated for 24 or 48 weeks with stavudine/lamivudine. RESULTS At the end of the follow-up, all patients acquired the lamivudine-associated mutation M184V. Only two subjects (4.5%) developed a TAM (T215Y; M41L), one subject developed a V75T/A mutation and one subject developed the particular MDR pattern F116Y, Q151M. CONCLUSIONS Our study clearly demonstrated that naive subjects treated with stavudine/lamivudine for 24-48 weeks selected a low rate of TAMs and MDR Q151M. One hypothesis explaining these results could be the development of the M184V mutation.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018119 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 2',3'-Didehydro-3'-deoxythymidine,D4T,2',3'-Didehydro-2',3'-dideoxythmidine,BMY-27857,Stavudine, Monosodium Salt,Zerit,2',3' Didehydro 3' deoxythymidine,BMY 27857,BMY27857
D019259 Lamivudine A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. 2',3'-Dideoxy-3'-thiacytidine,2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-,3TC Lamivudine,Lamivudine, (+)-cis-,Lamivudine, (+-)-trans-,BCH-189,Epivir,GR-109714X,GR109714X,Lamivudine, (2S-cis)-Isomer,2',3' Dideoxy 3' thiacytidine,BCH 189,BCH189,GR 109714X,Lamivudine, 3TC
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.
September 1999, AIDS (London, England),
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations.
December 2001, Journal of medical virology,
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.
September 2002, International journal of antimicrobial agents,
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
January 2004, The Journal of antimicrobial chemotherapy,
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
January 2018, Infectious disorders drug targets,
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.
January 1998, Journal of human virology,
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
February 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Reverse transcriptase inhibitors drug resistance mutations in drug-naive HIV type 1 positive Kenyans.
January 2011, East African medical journal,
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
January 1999, Journal of human virology,
M Mouroux, and D Descamps, and J Izopet, and A Yvon, and C Delaugerre, and S Matheron, and A Coutellier, and M A Valantin, and M Bonmarchand, and H Agut, and P Massip, and D Costagliola, and C Katlama, and F Brun-Vezinet, and V Calvez
Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients.
August 2006, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!